Biomarkers have improved the clinical application of numerous targeted agents used to treat solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific Val600 mutations of BRAF has increased the likelihood of response to certain agents aimed at inhibiting the mutant kinase. While dabrafenib is an effective anti-tumor agent with acceptable tolerability in patients with BRAF-mutated melanoma, we report the development (and outcome) of a previously unpublished acute toxic reaction observed in a patient receiving the drug.
SiegelRLMillerKDJemalA. Cancer statistics, 2016. CA: Cancer J Clinician2016; 66: 7–30.
2.
TarhiniAAKirkwoodJMGoodingWE. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol2007; 25: 3802–3807.
3.
KirkwoodJMManolaJIbrahimJ. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res2004; 10: 1670–1677.
4.
FlahertyKTInfanteJRDaudA. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med2012; 367: 1694–1703.
5.
LongGVStroyakovskiyDGogasH. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med2014; 371: 1877–1888.
6.
HauschildAGrobJJDemidovLV. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet2012; 380: 358–365.
7.
FlahertyKTRobertCHerseyP. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med2012; 367: 107–114.
8.
KhuranaADasanuCA. Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects!. J Oncol Pharm Practice2015; 21: 443–450.
9.
OzcanCWongSHariP. Reversible posterior leukoencephalopathy and bevacizumab. N Engl J Med2006; 354: 981–982.
10.
ZitoJALeeCCJohnsonS. Reversible posterior leukoencephalopathy syndrome after rituximab. Am J Emerg Med2010; 28: 537–537. e1–e2.
11.
MaurMItomaselloCFrassoldatiA. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol2012; 30: e76–e78.
12.
InfanteJRFecherLAFalchookGS. Safety, pharmacokinetic, pharmacodynamics, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol2012; 13: 773–781.
13.
FalchookGSLongGVKurzrockR. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet2012; 379: 1893–1901.
14.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
15.
CesariniLAlfieriPPantaleoniF. Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. Am J Med Genet A2009; 149A: 140–146.
